Robert Ross
Presidente en SURFACE ONCOLOGY, INC. .
Fortuna: - $ al 30/04/2024
Cargos activos de Robert Ross
| Empresas | Cargo | Inicio | Fin |
|---|---|---|---|
| SURFACE ONCOLOGY, INC. | Presidente | - | - |
| Director/Miembro de la Junta | 01/04/2021 | - | |
| Director Ejecutivo | 01/04/2021 | - | |
| Director Técnico/Científico/I+D | 01/10/2016 | 01/04/2021 | |
| XILIO THERAPEUTICS, INC. | Director/Miembro de la Junta | 16/06/2022 | - |
| Independent Dir/Board Member | 16/06/2022 | - | |
Obsidian Therapeutics, Inc.
 Obsidian Therapeutics, Inc. BiotechnologyHealth Technology Obsidian Therapeutics, Inc. develops cell and gene therapeutics that employ precise exogenous control of transgenes for improved safety and efficacy. The company was founded in 2016 and is headquartered in Cambridge, MA. | Director/Miembro de la Junta | 03/09/2020 | - |
Historial de carrera de Robert Ross
Antiguos cargos conocidos de Robert Ross.
| Empresas | Cargo | Inicio | Fin |
|---|---|---|---|
| BLUEBIRD BIO, INC. | Corporate Officer/Principal | 01/10/2012 | 01/10/2016 |
Formación de Robert Ross.
| Stanford University | Undergraduate Degree |
| Harvard Medical School | Graduate Degree |
| Columbia University College of Physicians & Surgeons | Graduate Degree |
Estadísticas
Internacional
| Estados Unidos | 8 |
Operativa
| Director/Board Member | 3 |
| Graduate Degree | 2 |
| Corporate Officer/Principal | 1 |
Sectorial
| Health Technology | 5 |
| Consumer Services | 4 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
| Empresas cotizadas | 2 |
|---|---|
| BLUEBIRD BIO, INC. | Health Technology |
| XILIO THERAPEUTICS, INC. | Health Technology |
| Empresas privadas | 2 |
|---|---|
Surface Oncology, Inc.
 Surface Oncology, Inc. BiotechnologyHealth Technology Surface Oncology, Inc. operates as a clinical-stage immuno-oncology company, which engages in the provision of biological pathways critical to the immunosuppressive tumor microenvironment for the development of next-generation cancer therapies. The firm’s pipeline includes wholly-owned lead programs targeting CD39 (SRF617) and IL-27 (SRF388), as well as a preclinical program focused on depleting tumor regulatory T cells via targeting CCR8 (SRF114). Its pipeline also includes licensed product programs, such as a collaboration with Novartis targeting CD73 (NZV930, Phase 1) and a collaboration with GlaxoSmithKline targeting PVRIG (SRF813, preclinical). The company was founded by David S. Grayzel in 2014 and is headquartered in Cambridge, MA. | Health Technology |
Obsidian Therapeutics, Inc.
Obsidian Therapeutics, Inc. BiotechnologyHealth Technology Obsidian Therapeutics, Inc. develops cell and gene therapeutics that employ precise exogenous control of transgenes for improved safety and efficacy. The company was founded in 2016 and is headquartered in Cambridge, MA. | Health Technology |
- Bolsa de valores
- Insiders
- Robert Ross
- Experiencia
